LGVN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):

Stats
Today's Volume	271 291
Average Volume	2.09M
Market Cap	8.73M
EPS	$0 ( 2024-02-27 )
Next earnings date	( $-2.15 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.180
ATR14	$0.00800 (0.44%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Hare Joshua	Buy	42 553	Class A Common Stock
2024-04-10	Hare Joshua	Buy	106 383	Class A Common Stock
2024-04-10	Hare Joshua	Buy	106 383	Warrant (right to buy)
2024-04-11	Hare Joshua	Buy	42 553	Warrant (right to buy)
2024-04-11	Hashad Mohamed Wa'el Ahmed	Buy	10 638	Class A Common Stock

INSIDER POWER
39.35
Last 100 transactions
Buy: 1 179 927 \| Sell: 679 611

Volume Correlation

Long: -0.11 (neutral)

Short: -0.50 (neutral)

Signal:(58.309) Neutral

Longeveron Inc. Class A Correlation

10 Most Positive Correlations
CNDT	0.902
SRTS	0.896
EWTX	0.89
PSTV	0.887
FOSL	0.885
NVIV	0.878
RUBY	0.877
CPIX	0.872
ATHE	0.871
GTEC	0.867

10 Most Negative Correlations
TYHT	-0.853
BLCT	-0.831
VERX	-0.81
OPCH	-0.808
DRNA	-0.806
UNCY	-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Longeveron Inc. Class A Correlation - Currency/Commodity

0.10
( neutral )

0.17
( neutral )

0.00
( neutral )

0.13
( neutral )

0.00
( neutral )

0.16
( neutral )

Longeveron Inc. Class A Financials

Annual	2023
Revenue:	$709 000
Gross Profit:	$-725 000 (-102.26 %)
EPS:	$-9.85

Q4	2023
Revenue:	$63 000.00
Gross Profit:	$-238 000 (-377.78 %)
EPS:	$-2.55

Q3	2023
Revenue:	$150 000
Gross Profit:	$54 000.00 (36.00 %)
EPS:	$-2.79

Q2	2023
Revenue:	$217 000
Gross Profit:	$93 000.00 (42.86 %)
EPS:	$-2.67

Financial Reports:

No articles found.

Longeveron Inc. Class A

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.